Eli Lilly surpasses Novo's golden diabetes drug

US pharmaceutical firm Eli Lilly has presented its long-awaited data for drug candidate tirzepatide in a direct comparison study with Novo Nordisk's semaglutide. The US candidate takes top prize.

Photo: Mike Blake/REUTERS / X00030

US firm Eli Lilly is well on the way to overtaking Danish pharmaceutical flagship Novo Nordisk.

This is by way of the drug candidate tirzepatide, which has surpassed Novo Nordisk's semaglutide, marketed as Ozempic, for example, for treating diabetes, according to an Eli Lilly statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs